Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Receivables - Accured (2024 - 2025)

PharmaCyte Biotech (PMCB) has disclosed Receivables - Accured for 2 consecutive years, with $287500.0 as the latest value for Q4 2025.

  • On a quarterly basis, Receivables - Accured changed N/A to $287500.0 in Q4 2025 year-over-year; TTM through Oct 2025 was $287500.0, a N/A change, with the full-year FY2025 number at $137500.0, changed 0.0% from a year prior.
  • Revenue - Other was -$1515.0 for Q2 2017 at PharmaCyte Biotech.
  • In the past five years, Receivables - Accured ranged from a high of $287500.0 in Q4 2025 to a low of $137500.0 in Q2 2024.